Tadalafil Tablet, Film Coated
Product Images NDC 47335-011

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 47335-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

Four line graphs showing the effect of Tadalafil versus placebo on blood pressure over time (hours). The graphs display changes in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure from 0 to 96 hours, with differences measured in mmHg. Error bars indicate variability at each time point.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

Two line graphs showing the effects on standing and supine systolic blood pressure (BP) over 24 hours post-dose. The top graph plots standing systolic BP (mmHg) with lines for Tadalafil 20 mg & doxazosin 8 mg and Placebo & doxazosin 8 mg. The bottom graph plots supine systolic BP (mmHg) with the same two treatment groups, displaying changes in BP over time in hours after dosing.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

A line graph showing the effect of 20 mg tadalafil and placebo, both combined with 8 mg doxazosin, on systolic blood pressure (mmHg) over 12 hours. The graph compares dosing at 08:00 and 20:00, illustrating changes in systolic blood pressure after administration of tadalafil or placebo.*

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) after different dosing regimens. The graph compares single 20-mg dose, single 5-mg dose, and once-daily 5-mg tadalafil following 5 consecutive days. The y-axis shows concentration ranging from 0 to 500 µg/L, and the x-axis covers 0 to 120 hours. Error bars indicate variability in measurements.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

Line graph showing change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score, ranging from 0 to -6. Tadalafil 5 mg shows a greater decrease in score over time than placebo, with a statistically significant difference at 12 weeks (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment duration comparing Tadalafil 5 mg with placebo. The graph plots weekly measurements, indicating Tadalafil 5 mg leads to a greater decrease in IPSS score compared to placebo, with statistical significance noted at certain points (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week duration of treatment for Tadalafil 5 mg and placebo groups. The y-axis shows change from baseline, and the x-axis shows treatment duration in weeks. Tadalafil 5 mg shows a greater decrease in IPSS score compared to placebo throughout the study period, with statistical significance indicated at week 12 (p<0.01).*

FDA Label Image

Spl-tadalafil-label-10mg (Spl Tadalafil Label 10mg)

Label for Tadalafil Tablets, USP 10 mg, oral film-coated tablets. The label specifies not to split tablets and to take the entire dose. It indicates a bottle containing 30 tablets for prescription use only, with the labeler name Sun Pharmaceutical Industries, Inc. and includes a barcode and product NDC 47335-011-83.*

FDA Label Image

Spl-tadalafil-label-20mg (Spl Tadalafil Label 20mg)

Tadalafil Tablets, USP 20 mg film-coated tablet label shows a 30-tablet prescription package from Sun Pharmaceutical Industries, Inc. It features the product name, strength, a barcode, and a warning not to split tablets and to take the entire dose. The label includes the NDC 47335-012-83 and instructions to open for full labeling.*

FDA Label Image

Spl-tadalafil-label-5mg (Spl Tadalafil Label 5mg)

Label for Tadalafil Tablets, USP 5 mg film-coated tablets by Sun Pharmaceutical Industries, Inc. The label specifies 'Do not split tablets; take the entire dose' and indicates the package contains 30 tablets for prescription use only (Rx only). The label includes a barcode and NDC 47335-010-83.*

FDA Label Image

Spl-tadalafil-showbox-1 (Spl Tadalafil Showbox 1)

Tadalafil Tablets USP 2.5 mg film-coated tablets packaging label for oral use by Sun Pharmaceutical Industries, Inc. The box contains 30 tablets (2 blister cards of 15 tablets) labeled for once daily use. Manufacturer and distributor details are from Sun Pharmaceutical Industries, Inc. and Sun Pharmaceutical Industries Limited, India.*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

Chemical structure of Tadalafil, as shown in the image. This structural diagram depicts the molecular arrangement of Tadalafil, a prescription drug available in film-coated tablet form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.